Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79871 | 0.80 | — | — | |
| SCHEMBL8119240 | 0.78 | — | — | |
| SCHEMBL14962814 | 0.78 | — | — | |
| SCHEMBL13485473 | 0.75 | — | — | |
| SCHEMBL22972244 | 0.75 | — | — | |
| SCHEMBL13629200 | 0.75 | — | — | |
| SCHEMBL11791240 | 0.73 | — | — | |
| SCHEMBL10703583 | 0.73 | PPARA (0.39) | ALDH1A1TSHR | |
| SCHEMBL56282 | 0.73 | THRB (0.33) | — | |
| SCHEMBL2957477 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963272-B1 | HYDROXYQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-03-20 | — | — | EP | claimed |
| US-8158799-B2 | Hydroxyquinoline derivatives | Merck Patent Gesellschaft MIT Meschraenkter Haftung (DE) | 2012-04-17 | — | — | US | claimed |
| EP-1963295-B1 | 3, 6-DIHYDRO-2-OXO-6H-(1,3,4)THIADIAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-08-03 | — | — | EP | claimed |
| EP-1951697-B1 | SUBSTITUTED 5-PHENYL-3,6-DIHYDRO-2-OXO-6H-[1,3,4]THIADIAZINES | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | claimed |
| US-7902186-B2 | Substituted 5-phenyl-3,6-dihydro-2-oxo-6H-1,3,4-thiadiazines | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | claimed |
| US-7534785-B2 | e.g.1-{3-[5-(4-chlorophenyl)-2-oxo-6H-1,3,4-thiadiazin-3-ylmethyl]phenyl}-3-(1-methylpyrrolidin-3-ylmethyl)urea; inhibitors of tyrosine kinases, in particular Met kinase; antitumor, antiinflammatory agent | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-19 | — | — | US | claimed |
| US-20080318936-A1 | Substituted 5-Phenyl-3,6-Dihydro-2-Oxo-6H-1,3,4-Thiadiazines | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-25 | — | — | US | claimed |
| US-20080312278-A1 | Hydroxyquinoline Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | claimed |
| US-20080306052-A1 | 3, 6-Dihydro-2-Oxo-6H-1,3,4,-Thiadiazine Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-11 | — | — | US | claimed |
| US-8158799-B2 | Hydroxyquinoline derivatives | Merck Patent Gesellschaft MIT Meschraenkter Haftung (DE) | 2012-04-17 | — | — | US | disclosed |
| US-7902186-B2 | Substituted 5-phenyl-3,6-dihydro-2-oxo-6H-1,3,4-thiadiazines | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | disclosed |
| US-20100004313-A1 | Modified Poloxamers for Gene Expression and Associated Methods | TBD | 2010-01-07 | — | — | US | disclosed |
| US-20100004313-A1 | Modified Poloxamers for Gene Expression and Associated Methods | TBD | 2010-01-07 | — | — | US | disclosed |
| US-7534785-B2 | e.g.1-{3-[5-(4-chlorophenyl)-2-oxo-6H-1,3,4-thiadiazin-3-ylmethyl]phenyl}-3-(1-methylpyrrolidin-3-ylmethyl)urea; inhibitors of tyrosine kinases, in particular Met kinase; antitumor, antiinflammatory agent | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20080318936-A1 | Substituted 5-Phenyl-3,6-Dihydro-2-Oxo-6H-1,3,4-Thiadiazines | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080312278-A1 | Hydroxyquinoline Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080306052-A1 | 3, 6-Dihydro-2-Oxo-6H-1,3,4,-Thiadiazine Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312278-A1 | Hydroxyquinoline Derivatives | MKI67, CCNT1, CCNY | DGAT1 3029/4885GAA 2405/4885ALDH1A1 820/4885 |
| US-20080318936-A1 | Substituted 5-Phenyl-3,6-Dihydro-2-Oxo-6H-1,3,4-Thiadiazines | ABL1, RET, ERBB2 | DGAT1 4343/4885GAA 4034/4885ALDH1A1 994/4885 |
| US-20100004313-A1 | Modified Poloxamers for Gene Expression and Associated Methods | POLRMT, POLM, POLN | DGAT1 3740/4885GAA 894/4885ALDH1A1 4239/4885 |
| US-20080306052-A1 | 3, 6-Dihydro-2-Oxo-6H-1,3,4,-Thiadiazine Derivatives | MET, ABL1, RET | DGAT1 3996/4885GAA 3743/4885ALDH1A1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.